SCHEMBL24008779

SCHEMBL24008779

Cc1ccc(NC(=O)Nc2nc(C)cc(NCCc3ccccc3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
MAPT P10636 5/20 0.53
HTT P42858 4/20 0.53
KDM4E B2RXH2 4/20 0.53
USP2 O75604 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ALDH1A1 P00352 3/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
SLC2A1 P11166 1/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
TP53 P04637 2/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
GBA1 P04062 1/20 0.46
NTRK1 P04629 2/20 0.45
HPGD P15428 1/20 0.45
NTRK2 Q16620 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258221 0.85 SMN1; SMN2 (0.49) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23258608 0.84 SMN1; SMN2 (0.63) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23258421 0.83 SMN1; SMN2 (0.43) LMNAMAPTHTTKDM4EUSP2
SCHEMBL25858313 0.83 SMN1; SMN2 (0.47) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23258674 0.83 SMN1; SMN2 (0.56) LMNAMAPTHTTKDM4EUSP2
SCHEMBL18053818 0.82 LMNA (0.54) LMNAMAPTHTTKDM4EUSP2
SCHEMBL18053838 0.82 LMNA (0.54) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23259004 0.82 SMN1; SMN2 (0.46) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23259109 0.82 DNM2 (0.51) LMNAMAPTHTTKDM4EUSP2
SCHEMBL23258620 0.82 SMN1; SMN2 (0.55) LMNAMAPTHTTKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG LMNA 4459/4885MAPT 1722/4885HTT 2086/4885
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG LMNA 4459/4885MAPT 1722/4885HTT 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.